吉西他滨联合铂类治疗晚期乳腺癌的临床观察

Clinical Observation of Gemcitabine Combined with Platinum for Advanced Breast Cancer

目的探讨吉西他滨联合顺铂治疗晚期乳腺癌的临床效果。方法将89例晚期乳腺癌患者随机分为2组,对照组(n=45)给予吉西他滨联合紫杉醇治疗,观察组(n=44)给予吉西他滨联合顺铂治疗。比较2组患者的临床效果。结果观察组和对照组的治疗有效率和疾病控制率分别为45.45%(20/44)、63.64%(28/44)和48.89%(22/45)、64.44%(29/45),组间比较无统计学差异(P>0.05);2组患者的中位生存时间分别为13.2个月和13.5个月,组间比较无统计学差异(P>0.05)。观察组的脱发不良反应发生率显著低于对照组(P<0.05)。结论吉西他滨联合顺铂治疗晚期乳腺癌的临床效果令人满意,不良反应轻,患者可耐受。

Objective To observe the clinical efficacy of gemcitabine combined with cisplatin for advanced breast cancer. Methods 89 patients with advanced breast cancer were randomly divided into 2 groups,the control group( n = 45) received gemcitabine combined with paclitaxel,the observation group( n = 44) received gemcitabine combined with cisplatin. The clinical efficacy of the 2 groups were compared. Results The treatment efficiency and disease control rates in the observation group and the control group were 45. 45%( 20 /44),63. 64%( 28 /44) and 48. 89%( 22 /45),64. 44%( 29 /45),there had no significant difference between the 2 groups( P > 0. 05); Median survival time of the 2 groups were 13. 2 months and 13. 5 months,respectively,there had no significant difference between the 2 groups( P > 0. 05); The incidence of hair loss in the observation group was significantly lower than that of the control group( P < 0. 05). Conclusion Gemcitabine combined with cisplatin for advanced breast cancer has satisfactory clinical effects with tolerable adverse reactions.